Also known as: Breezula, CB-03-01, Winlevi (acne formulation)
First-in-class topical androgen receptor antagonist; FDA-approved for acne, in trials for AGA.
Clascoterone is a topical androgen receptor (AR) inhibitor that competes with DHT for AR binding directly at the follicle. Unlike systemic anti-androgens, it is metabolized locally to cortexolone, minimizing systemic exposure. It blocks androgen signaling at the receptor level rather than reducing DHT production.
Unlock Premium Content
Get full access to in-depth analyses, cited studies, premium articles, and AI chat.
$12/mo
View pricing